25 September 2017

Oxford BioMedica to Present at Cantor Fitzgerald Healthcare Conference 2017, New York


Oxford, UK – 25 September 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces that Kyriacos Mitrophanous, Chief Scientific Officer, will be presenting at the Cantor Fitzgerald Healthcare Conference in New York on Wednesday 27 September at 16:35 Eastern Time. Stuart Paynter, Chief Financial Officer will also be attending the event.


- Ends -



For further information, please contact:



Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Stuart Paynter, Chief Financial Officer



Tel: +44 (0)1865 783 000

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton/Rosie Phillips


Tel: +44 (0)20 3709 5700


Notes for editors



About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases.  Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, Orchard Therapeutics and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products.  Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 280 people. Further information is available at www.oxfordbiomedica.co.uk.

Back to previous page